

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended): A method for the treatment of Alzheimer's disease, in a human, comprising administering to the human in need thereof an effective amount of an agent ~~which increases the insulin sensitivity of the human, with the proviso that said agent is not insulin-like growth factor or a dopamine agonist selected from the group consisting of troglitazone, ciglitazone, pioglitazone, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, and englitazone.~~

Claims 2-6 (cancelled)

7. (previously presented): The method of claim 25, wherein said thiazolidinedione is ~~troglitazone~~.

Claims 8-19 (cancelled)

20. (currently amended): A method of improving mentation of a patient with Alzheimer's disease, comprising administering to said patient an effective amount of an agent ~~which increases the insulin sensitivity of the patient selected from at least one member of the group of troglitazone, ciglitazone, pioglitazone, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, englitazone, and the pharmaceutically acceptable salts thereof.~~

21. (currently amended): The method of claim 25, wherein said thiazolidinedione is ~~5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiadiazolidine-2,4-dione pioglitazone.~~

22. (currently amended): The method of claim 25, wherein said thiazolidinedione is ~~5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiadiazolidine-2,4-dione pioglitazone hydrochloride.~~

23. (currently amended): The method of claim 25, wherein said thiazolidinedione is ~~5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiadiazolidine thiazolidine-2,4-dione.~~

24. (currently amended): The method of claim 25, wherein said thiazolidinedione is ~~5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiadiazolidine thiazolidine-2,4-dione maleate.~~

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

25. (currently amended): A method for the treatment of Alzheimer's disease, in a human, comprising administering to the human in need thereof an effective amount of a thiazolidinedione which increases the insulin sensitivity of the human selected from at least one member of the group of troglitazone, ciglitazone, pioglitazone, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, englitazone, and the pharmaceutically acceptable salts thereof.

26. (currently amended): The method of claim 20, wherein said thiazolidinedione agent is 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiadiazolidine-2,4-dione pioglitazone.

27. (currently amended): The method of claim 20, [.] wherein said thiazolidinedione agent is 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiadiazolidine-2,4-dione pioglitazone hydrochloride.

28. (currently amended): The method of claim 20, wherein said thiazolidinedione agent is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiadiazolidine thiazolidine-2,4-dione.

29. (currently amended): The method of claim 20, wherein said thiazolidinedione agent is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiadiazolidine thiazolidine-2,4-dione maleate.

30. (new): The method of claim 25, wherein said thiazolidinedione is pioglitazone or a pharmaceutically acceptable salt thereof.

31. (new): The method of claim 25, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof.

32. (new): The method of claim 20, wherein said agent is pioglitazone or a pharmaceutically acceptable salt thereof.

33. (new): The method of claim 20, wherein said agent is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof.

34. (new): The method of claim 25, wherein said thiazolidinedione is troglitazone or a pharmaceutically acceptable salt thereof.

35. (new): The method of claim 20, wherein said agent is troglitazone or a pharmaceutically acceptable salt thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com